TABLE 2.
Plasma HIV RNA values during ATI period
| Parameter | Placebo (n = 35) | Vaccine (n = 63) | Total (n = 98) |
|---|---|---|---|
| Maximum VL during ATI (log10 cp/ml)a | |||
| Mean (SD) | 5.39 (1.40) | 5.42 (1.17) | 5.41 (1.25) |
| Median (IQR) | 5.26 (4.58–7.00) | 5.15 (4.73–7.00) | 5.16 (4.70–7.00) |
| Range | 1.60–7.00 | 1.60–7.00 | 1.60–7.00 |
| ATI experience between W36 and W48, n (%) | 25 (71) | 46 (73) | 71 (72) |
| Time of maximum VL during ATI in participants having experienced ATI, n (%) | |||
| W38 | 2 (8) | 3 (7) | 5 (7) |
| W40 | 11 (44) | 13 (28) | 24 (34) |
| W42 | 8 (32) | 15 (33) | 23 (32) |
| W44 | 2 (8) | 9 (20) | 11 (15) |
| W48 | 2 (8) | 6 (13) | 8 (11) |
| Maximum VL during ATI (log10 cp/ml) in participants having experienced ATI | 6.12 | 5.95 | 6.12 |
| Participants with VL below 10,000 cp/ml at W48b (n [%]) | |||
| No | 17 (50) | 34 (56) | 51 (54) |
| Yes | 17 (50) | 27 (44) | 44 (46) |
a
P value for comparison of placebo vs. vaccine = 0.878.
b
Four participants did not resume ART at W36 and were considered in virological failure at W48.